Letrozole and Trenbolone Interaction: Avoid | Peptide Database

Join others researching Noopept — share findings, ask questions, and learn from real experiences Noopept (GVS-111, omberacetam) is a synthetic nootropic dipeptide developed at the Russian Academy of Medical Sciences in the 1990s. It is approved and marketed in Russia and several CIS countries for cognitive impairment of various origins, including post-traumatic and cerebrovascular conditions. Structurally related to the racetam family, Noopept is not technically a racetam itself but is often grouped with them due to a shared mechanism of action involving modulation of glutamatergic neurotransmission. Its standout characteristic is extraordinary potency -- roughly 1000 times more potent than piracetam by weight -- which allows effective dosing in the 10-30 mg range rather than the multi-gram doses required by piracetam. Noopept is rapidly absorbed and converted to its primary active metabolite, cycloprolylglycine, an endogenous neuropeptide that mediates much of the compound's sustained cognitive and neuroprotective activity. Noopept exerts its nootropic and neuroprotective effects through several interconnected mechanisms. It modulates glutamatergic neurotransmission by acting as a positive modulator at AMPA and NMDA receptors, enhancing long-term potentiation (LTP) in the hippocampus -- the core cellular process underlying memory formation. A defining feature of Noopept is its ability to increase the expression of both brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and cerebral cortex. BDNF supports synaptic plasticity, neuronal survival, and the growth of new dendritic connections, while NGF is critical for the maintenance and survival of cholinergic neurons in the basal forebrain, a population that degenerates in Alzheimer's disease. Noopept also exhibits antioxidant and anti-inflammatory properties, reducing oxidative stress and inhibiting neurotoxicity induced by excess calcium and glutamate. Additionally, it enhances the activity of inhibitory mechanisms that prevent excitotoxic neuronal damage. After oral administration, Noopept is rapidly metabolized to cycloprolylglycine, which crosses the blood-brain barrier and is thought to mediate much of the compound's longer-lasting neurotrophic activity.

Join others researching Thymogen — share findings, ask questions, and learn from real experiences Thymogen (EW dipeptide) is a Khavinson bioregulator consisting of glutamic acid and tryptophan, originally isolated from calf thymus extracts (Thymalin) in the late 1980s. Developed by Professor Vladimir Khavinson, it has been registered in Russia since 1990 in multiple forms including injectable solution, nasal spray, and topical cream. Thymogen modulates both humoral and cellular immunity, activates T-cell differentiation, and has demonstrated geroprotective (anti-aging) and antitumor activities in research studies. Thymogen works through multiple immunomodulatory mechanisms: (1) activates T-cell differentiation and T-cell recognition of peptide-MHC complexes, (2) induces changes in intracellular cyclic nucleotide composition, (3) activates neutrophilic chemotaxis and phagocytosis, (4) normalizes T-lymphocyte concentrations and ratios (CD3+, CD4+, CD8+), (5) stimulates production of immunoglobulins (IgA, IgG, IgE, IgM), and (6) enhances lymphocyte differentiation receptor expression. Research suggests Thymogen may interact specifically with the AACG DNA sequence, affecting gene expression. The peptide is rapidly distributed to thymus, lymph nodes, liver, adrenals, and kidneys.